At a time when the future of the program is in doubt due to possibly severe budget cuts to the US State Department (where PEPFAR is based) proposed by the new administration, we thought it would be an opportune moment to highlight some of the key studies we have published exploring PEPFAR’s role in fighting the HIV/AIDS epidemic.
19 April 2017 | Health Affairs
Please read and share this letter signed by the European AIDS Treatment Group and the PrEP in Europe Initiative (PEI), a partnership of European prevention and policy NGOs. It requests Gilead Sciences to surrender their patent of Truvada® or otherwise make it possible for Truvada or generic equivalents of it to be offered at greatly reduced prices to all European health care systems so that it can be used as HIV pre-exposure prophylaxis (PrEP).
18 April 2017 | EATG / PrEP in Europe
PEPFAR is a standout example of how to achieve great things through strategic U.S. foreign-assistance investments — and of how public–private partnerships can wed the efficiencies of the private sector with the scale and reach of the public sector. By maintaining the program’s funding — something we both advocate — the United States and this administration will be well positioned to celebrate a historic public-health achievement: the end of the AIDS epidemic for an entire generation of children.
10 April 2017 | National Review
Former U.S. President George W. Bush touted his signature aid project for Africa during a visit to Botswana on Tuesday, saying he hoped Washington would recognise its importance in saving lives threatened by AIDS.
05 April 2017 | Reuters
President Donald Trump included a chilling proposal last week in his request for the as yet unresolved 2017 federal budget: slash funding for the wildly successful and bipartisan-backed President’s Emergency Plan for AIDS Relief (PEPFAR) by $300 million and "begin slowing the rate of new patients on treatment in FY 17."
05 April 2017 | Health GAP
The United States will meet its commitment to the Global Fund, according to the budget blueprint which President Donald Trump sent to Congress in March. During the most recent replenishment drive for the Global Fund, the U.S., under the Obama administration, pledged $4.3 billion for 2017-2019, or $1.43 billion a year.
05 April 2017 | Global Fund Observer
In January 2017, the Ministry of Finance of the Russian Federation rejected a request to allocate $1.2 billion over four years for the response to HIV, citing “a lack of federal funds.” The Ministry of Health had asked for the funds in order to implement the National AIDS Strategy 2017-2020. The rejection of the funding request once again brought into question the ability and willingness of the Russian Federation to manage its serious HIV epidemic.
04 April 2017 | Global Fund Observer
In some parts of the country we heard that clinics have been closed, moved to less convenient locations or their opening hours reduced. Some clinics are being run with less consultant input, which some see as an efficiency saving but others see as a safety concern. A recent survey shows that patients with STI symptoms are finding it more difficult to access appointments within 48 hours. We were particularly concerned about cuts to health adviser posts in clinics.
03 April 2017 | King's Fund
Pharma and patient groups are dismayed by new cost-capping and delaying measures, which they say will further restrict access to new medicines in England.
27 March 2017 | PharmaPhorum
A healthy relationship is possible if based on integrity, independence, accountability, and transparency.
27 March 2017 | BMJ